NCT04922788View on ClinicalTrials.gov

Study to Evaluate the Safety, Immunogenicity, and Efficacy of Nanocovax Vaccine Against COVID-19

PHASE3CompletedINTERVENTIONAL
Enrollment

13,006

Participants

Timeline

Start Date

June 7, 2021

Primary Completion Date

July 20, 2022

Study Completion Date

July 20, 2022

Conditions
SARS-CoV-2 InfectionCOVID-19
Interventions
BIOLOGICAL

Nanocovax

Recombinant Protein spike (s) SARS-CoV-2 and 0,5 mg Aluminum adjuvant

BIOLOGICAL

Placebo

0,5 mg Aluminum adjuvant

Trial Locations (1)

Unknown

Military Medical Academy, Hanoi

Sponsors
All Listed Sponsors
lead

Nanogen Pharmaceutical Biotechnology Joint Stock Company

INDUSTRY

NCT04922788 - Study to Evaluate the Safety, Immunogenicity, and Efficacy of Nanocovax Vaccine Against COVID-19 | Biotech Hunter | Biotech Hunter